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The Importance of Individualized Pharmaceutical
Therapy in the Treatment of Diabetes Mellitus
DAVID B. NASH, M.D., M.B.A., JENNIFER B. KOENIG, M.S., KAREN D. NOVIELLI, M.D., 
RENEE LIBERONI, M.P.H., and MIRIAM REISMAN, M.F.A.
ABSTRACT
Individualized pharmaceutical care for patients with diabetes is necessary for several reasons.
First, diabetes is a highly complex disease caused by the interplay among genetic, physio-
logical, and environmental factors that vary from individual to individual. Second, the pro-
file of patients with diabetes has evolved to include people of all ages and socioeconomic
backgrounds, with varying medical histories and health behaviors. Third, diabetes often oc-
curs concurrently with other medical conditions, especially in certain groups, such as the el-
derly. While the treatment goals for all patients with diabetes are the same—to stabilize and
maintain healthy blood glucose levels to prevent serious complications—the treatment plan
used to achieve those goals will vary among individuals. There are many clinically proven
options available for the treatment of diabetes. While there are well-established guidelines
regarding which intervention is the best option for patients with either type 1 or type 2 dia-
betes, individual patient characteristics and needs should drive the care process. Assuring pa-
tient access to the wide variety of medications is crucial to meeting these needs and achiev-
ing quality, cost-effective diabetes management.
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EXECUTIVE SUMMARY
DIABETES MELLITUS is a complex disease witha prevalence that is rapidly growing, es-
pecially among certain groups of Americans.
In the United States nearly 6% of the total pop-
ulation (approximately 16 million people) has
diabetes.1 Hispanics, African Americans, the
elderly, children, and the clinically obese are at
high risk for the disease.1–5 The impact of dia-
betes is felt economically, clinically, and so-
cially. This chronic condition drains limited
healthcare dollars, tests the boundaries of clin-
ical resources, and decreases quality of life for
patients and their families.
The insidious nature of diabetes compounds
the threats it poses; up to one third of people
with diabetes in America are undiagnosed,1 de-
spite the fact that diabetes can be identified
through a simple blood test.3 But patients are
often asymptomatic in the early stages, going
untreated until their bodies have sustained ir-
reversible damage. These effects take a high toll
on individual patients and on America’s
healthcare system overall. Diabetes is the sixth
leading cause of death from disease, and its
combined direct and indirect costs total nearly
$100 billion annually.2
Controlling diabetes is a clinical challenge for
several reasons. First, diabetes is a highly com-
plex illness caused by the interplay among ge-
netic, physiologic, and environmental factors
that vary from individual to individual.6 Care-
ful monitoring and intensive therapy are re-
quired to avoid serious complications. As en-
vironmental and physiologic factors fluctuate,
drug therapy that was once effective may re-
quire modification.
Second, the diabetic population is changing.
At one time, diabetes was primarily considered
a disease of people with atypical genes (type 1)
or long lifespans (type 2). Now, epidemiolo-
gists know that diabetes affects a larger, more
diverse group of people. While socioeconomic
and technological changes have caused Amer-
icans to live longer (thanks to modern medi-
cine), they have also encouraged unhealthy
lifestyles (thanks to modern conveniences),
putting more people at greater risk for devel-
oping diabetes today.7–8 In addition, there is
greater diversity among individuals who de-
velop diabetes. For example, in the past, dia-
betes in children was almost always type 1; re-
cently, increases in childhood type 2 diabetes
have been reported.1 Although similar in age,
a child with type 1 diabetes would need a dif-
ferent treatment plan than a child with type 2
diabetes. Greater patient diversity warrants
greater therapeutic diversity.9
Third, diabetes often occurs along with other
medical conditions, especially in the el-
derly.11–14 Diseases that frequently coexist with
diabetes include cardiovascular disease, de-
pression, obesity, and arthritis. Diabetes with
comorbid conditions presents a greater treat-
ment challenge due to potential disease syner-
gies, drug interactions, and compromised
physiologic reserves.9
The profile of patients with diabetes has
evolved to include people of all ages and so-
cioeconomic backgrounds, with varying med-
ical histories and health behaviors. As the pa-
tient population diversifies, management of
diabetes must address the differences among in-
dividual patients.9 While the treatment goals for
all people with diabetes are the same—to stabi-
lize and maintain healthy blood glucose levels
to prevent serious complications—the treatment
plan used to achieve those goals will vary. Imag-
ine three patients: an 8-year-old male with type
1 diabetes but no other health problems, a 48-
year-old female with mild type 2 diabetes and
coexisting heart disease, and a 72-year-old male
with advanced type 2 diabetes and significant
diabetes-related sequelae. The clinical differ-
ences alone call for somewhat different treat-
ment plans. When socioeconomic variables are
added to the mix (e.g., diet, exercise, living en-
vironment, availability of medications, involve-
ment of caregivers), markedly different man-
agement strategies may be required.
Fortunately, the past few decades have seen
the development of a myriad of treatment op-
tions to address the specific needs of individu-
als with diabetes. Breakthrough innovations in-
clude the synthesis of human insulin in the
1980s and effective insulin analogues with im-
proved properties in the 1990s. Incremental in-
novations in pharmacotherapy have been
equally valuable in children and elderly pa-
tients with diabetes.9 For instance, alternative
dosage forms encourage patient adherence by
meeting patient-specific needs,15 and newer in-
sulin analogues offer improved side effect pro-
files.16 Recombinant DNA technology has
made some of these innovations possible, and
biomedical technologies will continue to play
an important role in future research and de-
velopment.17–19 Treatments for type 2 diabetes
have also been expanded to include more than
20 different medications that reduce blood glu-
cose levels in several different ways. The vari-
ety of medications helps patients who are
prone to side effects or have difficulty adher-
ing to their regimens to find a management
plan that is effective for them. Newer oral dia-
betes medications have reduced the potential
for hypoglycemic reactions, and increased op-
tions encourage adherence to treatment plans.
Yet despite the improvements in diabetes
treatment and education, the prevalence of the
terrible consequences of diabetes continues to
increase at an alarming rate. Therefore, still
greater efforts are necessary. To this end, we
offer this paper as a diabetes management ap-
proach that may help thwart the disease and
its high human and economic costs. This ap-
proach focuses on the benefits of individual-
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ized diabetes care. With the many pharmaceu-
tical options available today, treatment can be
tailored to specific patients and groups. But the
availability of these medications is not enough.
High-quality, cost-effective diabetes care can
be achieved only if: (1) the patient’s specific
needs are accurately identified, and (2) there is
access to the wide variety of diabetes drugs to
match these needs. To foster a successful match
between each patient and his or her drug ther-
apy, many factors—clinical, social, and eco-
nomic—must be considered. The final section
of the paper provides a simple tool that en-
courages patients, providers, and policy-mak-
ers to bear in mind the key aspects of individ-
ualized care in the fight against diabetes.
INTRODUCTION: DIABETES BASICS
Epidemiology of diabetes
In the United States nearly 6% of the total pop-
ulation (or 15.7 million people) has diabetes. Di-
abetes contributes to more than 193,000 deaths
per year, and its annual incidence has increased
sixfold since 1958.1 Diabetes has become more
prevalent over the last two decades. The inci-
dence of diabetes began rising in the early 1980s,
leveled off in the middle of the decade, and then
increased sharply in the 1990s. Between 1980
and 1996, the number of persons with diagnosed
diabetes in the United States increased from 5.8
million to 8.5 million.20 By 1997, the number of
persons with diagnosed diabetes had risen to
10.3 million, with 798,000 new cases diagnosed
per year; an additional 5.4 million are believed
to have undiagnosed diabetes. Diabetes is a
growing problem among the elderly, children
and adolescents, and the clinically obese. Cer-
tain ethnic groups, such as Native Americans,
Latinos, and African Americans, are also at
greater risk for the disease (Table 1).2,3
The number of persons with diagnosed dia-
betes, particularly type 2 diabetes, is increasing
for several reasons: (1) improvements in
screening and change in the diagnostic criteria
from a fasting plasma glucose greater than or
equal to 140 to one that is greater than or equal
to 126; (2) increasing rates of obesity and seden-
tary lifestyles; (3) growth in populations that
have high rates of type 2 diabetes21; (4) recog-
nition that type 2 diabetes is an increasing
problem in children and adolescents22; and (5)
an aging population.
Definition of types 1 and 2
Diabetes mellitus is a group of diseases in
which hyperglycemia (elevated blood glucose)
results from inadequate production or use of in-
sulin, the hormone secreted by the pancreas that
lowers blood sugar. Insulin is an essential ele-
ment for many bodily functions: it allows glu-
cose (sugar) to enter body cells where it is used
as energy, and it helps the body synthesize pro-
tein and store fat. When insulin availability or
function is compromised, glucose and lipids re-
main in the bloodstream instead of being con-
verted to energy. Over time, excess glucose and
lipids damage the body’s organs, having par-
ticularly deleterious effects on the heart.1
Diabetes occurs in two forms: type 1, previ-
ously called insulin–dependent diabetes melli-
tus, and type 2, previously called non-in-
sulin–dependent diabetes mellitus. Table 2
compares the features of the two major types
of diabetes. In type 1 diabetes, the body com-
pletely lacks insulin. This type of diabetes gen-
erally appears in patients before the age of 18
and accounts for about 5%–10% of all cases of
diabetes mellitus. It is caused by an autoim-
mune process that destroys the insulin-pro-
ducing cells of the pancreas. Although a dia-
betes-specific diet, moderate exercise, and
other healthy habits can help patients reduce
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TABLE 1. PREVALENCE OF DIABETES IN
DIFFERENT ETHNIC GROUPS COMPARED TO
OVERALL U.S. POPULATION
Percentage of persons
Subgroup with diabetes
Puerto Ricans 26
Mexican Americans 24
Cuban Americans 16
Native Americans 12
African Americans 11
Overall U.S. population 6
their glucose levels and avoid complications,
type 1 diabetes always requires insulin therapy
to counterbalance the absence of naturally oc-
curring insulin.23
Type 2 diabetes is the most common form of
diabetes, representing 90%–95% of all cases di-
agnosed. In type 2 diabetes, the body is either
deficient in its insulin production, or resistant to
insulin, or both. Insulin resistance occurs when
the body’s cells no longer respond properly to
insulin and their ability to take up glucose is im-
paired, although insulin is available. Most type
2 diabetes develops in adulthood, although re-
cent increases in children represent an alarming
trend. Their increases appear to correspond with
increases in obesity and inactivity among this age
group. Generally, patients with type 2 diabetes
are obese.23 Other rare, nonchronic forms of di-
abetes account for 1%–2% of all diagnosed cases.
Symptomatology
Although all people with type 1 diabetes de-
velop symptoms, only approximately one third
of type 2 sufferers do, perhaps accounting for
the large number of undiagnosed cases. Symp-
toms common to both types of diabetes include
frequent urination or need to urinate, excessive
thirst, extreme hunger, fatigue, unusual weight
loss, and irritability.24
Risk factors and diagnostics
Although diabetes goes undetected in many
people, a lack of diagnostic tests is not the prob-
lem. Diagnosing diabetes is as simple as deter-
mining a plasma glucose level using a simple
blood test. Two consecutive days of either a
fasting glucose level of 126 mg/dL or greater
or a nonfasting glucose level of 200 mg/dL or
greater with symptoms indicates diabetes.3
The real problem with diagnosing diabetes is
getting people at risk tested for the disease.
Many people are not aware that they are at risk
or already have diabetes. Risk factors for type
2 diabetes include obesity, advanced age (45
years and over), family history, ethnicity, mal-
nutrition, inactivity, dyslipidemia (high choles-
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TABLE 2. COMPARISON OF TYPE 1 AND TYPE 2 DIABETES
Type 1 diabetes Type 2 diabetes
Prevalence 5–10% of cases 90–95% of cases
Age of onset Usually before 18 Usually after 45
Cause Body’s inability to produce Body’s inability to produce
insulin enough insulin or resistance to
insulin
Common symptoms Frequent urination or need to Same as type 1 symptoms
urinate; excessive thirst; and blurred vision; tingling in
extreme hunger; fatigue; hands or feet; increased
unusual weight loss; irritability susceptibility to infection; slow
to heal cuts and bruises;
recurring skin, gum or bladder
infections
Number with disease who 100% 33%
develop symptoms
Risk factors Exposure to environmental Obesity; advancing age (451);
triggers (i.e., unidentified family history; ethnicity;
virus); having sibling or parent malnutrition; inactivity; high
with type 1 diabetes cholesterol levels; history of
gestational diabetes; having a
baby weighing 9 lbs. or more at
birth
Treatment Diet control; exercise; home Diet control; exercise; home
blood glucose testing; and blood glucose testing; and, in
daily insulin injections some cases, oral medication
and/or insulin
terol levels), and history of gestational diabetes
or bearing a child weighing more than nine
pounds at birth.23 Anyone with one or more of
these risk factors should be tested for diabetes.
Consequences of untreated or inadequately 
treated diabetes
Untreated type 1 diabetes has serious reper-
cussions, specifically ketoacidosis. Ketoacido-
sis, also known as diabetic coma, is a metabolic
crisis that occurs when poorly controlled dia-
betes causes high blood glucose levels. If no
medical intervention occurs, ketoacidosis can
lead to coma and death. When type 2 diabetes
goes undetected and untreated, complications
develop more slowly than in type 1 diabetes
but can be just as serious.23,24 These complica-
tions may include one or more of the follow-
ing conditions: eye disease and blindness,
nerve damage, kidney failure, foot and leg ul-
cers that can lead to amputation, heart disease,
stroke, and narrowing of the arteries. These
complications also may occur in patients with
type 1 disease.
Untreated or inadequately treated diabetes
and its resultant complications cause substan-
tial clinical and economic burdens of nearly
$100 billion annually. Substantial costs are in-
curred not only for diabetes-related direct med-
ical expenditures, but also for the indirect costs
of disability and lost productivity resulting
from diabetes-related morbidity and prema-
ture mortality.25 According to the American Di-
abetes Association, the total estimated annual
economic cost of diabetes in the United States
in 1997 was $98 billion dollars. This figure in-
cludes $44 billion in direct medical and treat-
ment costs and $54 billion for indirect costs at-
tributed to disability and mortality. In 1997, the
per capita costs of healthcare for people with
diabetes amounted to $10,071, compared with
$2,699 for people without diabetes.25
Diabetes management
Studies have proven that diabetic complica-
tions can be minimized or avoided by main-
taining normal or near-normal blood glucose
levels. The Diabetes Control and Complica-
tions Trial (DCCT), a landmark 10-year clinical
study, established that intensive treatment of
diabetes delays the onset and slows the pro-
gression of diabetes complications.27 The
DCCT confirmed that maintaining a healthy
blood glucose level at an average of 155 mg/dL
reduces the long-term risk of nerve and eye
damage and kidney disease.27 The patients
studied in the DCCT were under 40 years old
and were diagnosed with type 1 diabetes; how-
ever, analogous findings have been docu-
mented in older patient populations with either
type 1 or type 2 diabetes.
Early intervention may be the key to limit-
ing the severity of diabetes complications.28
The United Kingdom Prospective Diabetes
Study (UKPDS), the most comprehensive study
of patients with type 2 diabetes to date, fol-
lowed 5,102 persons newly diagnosed with
type 2 diabetes for an average of 10 years. This
study confirmed and extended previous evi-
dence in support of the hypotheses that hy-
perglycemia is a major cause of the micro-
vascular complications of diabetes, and that
cardiovascular outcomes are consistently asso-
ciated with hyperglycemia irrespective of its
underlying cause.29
Based on the DCCT and other important di-
abetes studies, the American Diabetes Associ-
ation states that strict blood glucose control can
have similar benefits in all types of diabetes be-
cause the complications of uncontrolled hy-
perglycemia develop through similar patholo-
gies, regardless of how the underlying disease
occurs. In other words, while type 1 and type
2 diabetes may not always be treated using the
same therapies, the end result of any effective
therapy—a consistently healthy blood glucose
level—will prevent or delay complications in
either condition. Details about diabetes treat-
ment options are described in the subsequent
section.
PHARMACOLOGIC MANAGEMENT
OPTIONS FOR DIABETES
There are many clinically proven pharmaco-
logic and nonpharmacologic interventions to
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control blood glucose levels for people with di-
abetes. Nonpharmacologic interventions in-
clude diet, exercise, and other behavioral mod-
ifications. Proper nutrition and exercise are a
fundamental part of treating both type 1 and
type 2 diabetes.
Pharmacologic treatment guidelines differ
for type 1 and type 2 diabetes. Because people
with type 1 diabetes cannot produce any in-
sulin, they must inject it daily. Insulin reduces
glucose levels by suppressing glucose produc-
tion in the liver and by increasing glucose uti-
lization after meals.30 A patient with type 2 di-
abetes may require oral drug therapy alone or
in combination with insulin therapy.
Well-established clinical practice recommen-
dations generally guide the decision regarding
which intervention is the best option for dia-
betes patients.26 But individual patient charac-
teristics should drive the care process, suggest-
ing where interventions should begin, and in
which direction care will proceed. Because dia-
betes is a progressive, incurable illness, the
pathways are multidirectional and dynamic;
that is, interventions almost always need mod-
ification over a patient’s lifetime.
Nonpharmacologic management: the first line of
defense against diabetes
The first interventions in diabetes manage-
ment are nonpharmacologic. Even for patients
with type 1 diabetes, for whom insulin ther-
apy is always required, it is also important to
use nonpharmacologic strategies to control
blood glucose levels and to improve general
health. For patients with type 2 diabetes, non-
pharmacologic interventions may be enough
to control diabetes, at least initially. Nonphar-
macologic interventions control blood glucose
levels by balancing insulin production and
sensitivity with nutrition and exercise. First-
line therapy for type 2 diabetes calls for an ad-
justment in diet and exercise; for overweight
patients, often a short trial of weight reduction
and exercise is recommended before the initi-
ation of pharmacotherapy.26 Exercise can fa-
cilitate weight loss, and it helps to improve in-
sulin sensitivity, allowing the body to use
insulin more efficiently. In addition to lower-
ing blood glucose levels, diet and exercise can
help improve a patient’s lipid profile (i.e., reduce
cholesterol levels), which is important for avoid-
ing the cardiovascular complications of dia-
betes. Other behavior modifications, such as
avoiding alcohol and tobacco, can also help
manage diabetes and its complications.
Oral drug therapy
If and when nonpharmacologic treatment no
longer controls blood glucose levels ade-
quately, oral antidiabetic medications are gen-
erally the next step for people with type 2 dia-
betes. These medications may be used alone, in
combination with one another, or as an adjunct
to insulin. Oral medications for diabetes reduce
blood glucose levels in several different ways.
Some increase the amount of insulin secreted
from the pancreatic beta cells. Others allow the
body to use the insulin that is already present
more effectively. A third group reduces the
breakdown of carbohydrates in the gastroin-
testinal tract so that less sugar is absorbed.
Some medications use a combination of these
methods to manage blood glucose levels.
No single currently available agent appears
to be superior when used as monotherapy, and
combination therapy is often indicated. Many
people with diabetes need to use more than one
kind of medication to manage both their insulin
production and insulin resistance. If a patient
does not respond to a first-line agent, a second
agent is typically added, not substituted.31
It is important to note that people with type
2 diabetes are not the only patients who may
benefit from noninsulin oral medications. Al-
though oral antidiabetic agents cannot be used
as primary therapy for persons suffering from
type 1 diabetes, these individuals may also ben-
efit from therapy with a combination of oral
drugs and insulin. For example, a-glucosidase
inhibitors used in addition to an insulin regi-
men have decreased the early peak in blood
glucose following meals, thus minimizing the
subsequent drop in plasma glucose, evening
out glucose levels overall.32
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The remainder of this section describes the
major classes of noninsulin oral drug therapy
available for the treatment of diabetes.
Sulfonylureas. Sulfonylureas work in two ways:
they increase insulin production and reduce in-
sulin resistance. They are taken one or more times
a day and require careful monitoring to avoid a
low blood sugar reaction (hypoglycemia). This
class includes the following drugs:
First Generation Second Generation
 Acetohexamide  Glimepiride
 Chlorpropamide  Glipizide
 Tolazamide  Glyburide
 Tolbutamide
The decision to use a sulfonylurea and the
choice among the available agents will depend
greatly on the individual characteristics of the
patient. Generally, second-generation sulfonyl-
ureas are preferable because they interact with
fewer drugs and have a more favorable side ef-
fect profile. They are long-acting, allowing for
once-daily dosing that may encourage adher-
ence to drug regimens. Sulfonylureas with short
half-lives tend to minimize hypoglycemic
episodes; patients prone to such episodes will
usually benefit from shorter acting agents such
as glipizide and should avoid the long-acting
medications such as chlorpropamide. Patients
with compromised kidney or liver function
should be monitored especially closely when
taking sulfonylureas because these drugs are
processed renally and hepatically. This applies
to the elderly and patients with comorbid dis-
ease(s) that affect these organs.9 For these indi-
viduals, dosages should begin low (about half
the recommended starting dose) and be titrated
cautiously. Sulfonylureas are not indicated for
patients with severe kidney or liver disease.
Biguanide. An alternative or adjunct to sul-
fonylureas is metformin, the only currently
available biguanide. It controls blood glucose
levels by acting on the liver to ensure that it
does not produce excessive amounts of sugar.16
An additional benefit of metformin is that it
promotes weight loss and reduction in blood fat
and cholesterol levels, all of which can contrib-
ute to better blood glucose control. However,
alcohol use or kidney disease may preclude the
use of this agent. Metformin (Bristol-Myers
Squibb Co., Princeton, NJ) can also encourage
anorexia, so it may not be preferable for older
patients for whom malnutrition is a concern. In
general, though, this agent is a good option for
the elderly because unlike sulfonylureas and in-
sulin, metformin does not contribute to hypo-
glycemia.9 Metformin is generally taken two or
three times per day with meals.
a-Glucosidase inhibitors. a-Glucosidase inhib-
itors function by blocking gastrointestinal en-
zymes that digest carbohydrates, thus slowing
and reducing the production of sugar from
these foods. Two a-glucosidase inhibitors are
currently available: acarbose and miglitol. To
maximize effectiveness, these medications are
taken three times daily at mealtime. Like met-
formin, a-glucosidase inhibitors do not cause
hypoglycemia when taken alone. Acarbose also
has a stool-softening effect that may be desir-
able in patients prone to constipation.16
Thiazoldinediones. The thiazolidinediones in-
clude rosiglitazone and pioglitazone. The first
thiazolidinediones, troglitazone, was removed
from the U.S. market because of rare but severe
hepatotoxicity.16 Thiazolidinediones are indi-
cated for type 2 diabetes; they sensitize the
body to its own insulin or to insulin therapy.
They can be used alone or with other medica-
tions such as metformin, sulfonylureas, or in-
sulin; however, they have not been tested with
a-glucosidase inhibitors. Taken alone, thiazo-
lidinediones do not cause hypoglycemia; with
insulin or insulin analogues hypoglycemia can
occur. The currently available thiazolidine-
diones can have a positive effect on the lipid
profiles, and they do not have adverse effects
on the liver or kidneys. Thiazolidinediones can
reduce the effectiveness of oral contraceptives.
New combined oral medications. In August 2000,
the Food and Drug Administration (FDA) ap-
proved the first fixed dose combination oral an-
tidiabetic, Glucovance (Bristol-Myers Squibb
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Co., Princeton, NJ). Glucovance combines the
two most often prescribed oral diabetes med-
ications—glyburide and metformin—in one
tablet. This new approach to the management
of type 2 diabetes is indicated as first-line ther-
apy for newly diagnosed diabetes, and is also
indicated as second-line therapy for patients
who have been taking metformin or a sulfonyl-
urea alone without clinical success.34
Insulin and insulin analogues. Insulin or in-
sulin analogs are required for all people with
type 1 diabetes and some people with type 2
diabetes to maintain adequate blood glucose
control. Because of progressive decline in beta
cell function in type 2 diabetes, even the use of
multiple oral medications is sometimes not ad-
equate, and eventually many people with type
2 diabetes will require insulin therapy either in
combination with the oral therapies or instead
of them.30 Currently 40% of people with type
2 diabetes use insulin. The need for insulin in-
creases with duration of the disease.30
Today, there are more than 20 types of FDA-
approved insulin available in the United States.35
Insulin therapies vary in how they are manufac-
tured, how they function in the body, and how
they are administered. Because each person re-
sponds to insulin uniquely, these different treat-
ment options allow therapy to be individualized
to meet the needs of specific patients.
Varieties of insulin by species type. Insulin can
be derived from several animal species. In the
past, insulin derived from cows and pigs was
used to treat diabetes. Synthetic human insulin,
developed using recombinant DNA technology,
is now used. Bovine (cow) and porcine (pig) in-
sulins were extracted from the pancreas and
processed so the human body would accept it.9
However, allergic reactions occurred in some
individuals who used insulin from nonhuman
sources. Human insulin is not extracted from
humans but synthesized in laboratories and is
identical to the naturally occurring insulin.36
Varieties of insulin by duration of action. The
availability of many types of insulin with vary-
ing durations of action provides options for pa-
tients with diverse needs. Insulin may be rapid-
acting, short-acting, intermediate-acting, or
long-acting. Rapid-acting insulin (Lispro, Eli
Lilly and Co., Indianapolis, IN) reaches the
blood within 15 minutes after injection. It peaks
30 to 90 minutes later and may last as long as
5 hours. Short-acting (regular) insulin usually
reaches the blood within 30 minutes after in-
jection. It peaks 2 to 4 hours later and stays in
the blood for about 4 to 8 hours. Intermediate-
acting (NPH [neutral protamine Hagedorn]
and lente) insulins reach the blood 2 to 6 hours
after injection. They peak 4 to 14 hours later
and stay in the blood for about 14 to 20 hours.
Ultralente insulin is a long-acting insulin that
takes 6 to 14 hours to start working. It has no
peak or a very small peak 10 to 16 hours after
injection. It stays in the blood between 20 and
24 hours. Insulin glargine is a long-acting in-
sulin with a relatively constant blood level over
24 hours without a peak.
Because it is common for people with diabetes
to use more than one type of insulin, some in-
sulins are available as combination therapies.
For example, a combination of regular insulin
and NPH insulin is available as a premixed so-
lution. This can be convenient because it reduces
the number of injections required to control
blood glucose. However, the ratio of insulins
cannot be adjusted as needed. For this reason,
some patients prefer to mix their own insulin.
Varieties of insulin by method of delivery. Most
often, insulin is self-injected subcutaneously 2
to 4 times per day. Traditionally, syringes are
used, but special delivery devices such as in-
sulin pumps and pens are also available. Al-
though these devices still use a needle, some
patients are more comfortable using them.
Insulin pens can be a convenient option. The
pen contains a premeasured amount of insulin,
but patients can use variable amounts depend-
ing on their particular needs at the time of dos-
ing. The pen has a dial that is turned to select
the amount of insulin desired. After an insulin
pen has been opened, it can be stored at room
temperature and reused over a period of days.
NASH ET AL.S-12
However, patients should use a replacement
needle for each injection.16
Continuous subcutaneous insulin infusion us-
ing a pump is another option for insulin deliv-
ery. Insulin pumps, which were first developed
20 years ago, provide a continuous flow of in-
sulin to the blood that more closely mimics the
way the body produces its own insulin com-
pared to daily injections. The design and tech-
nology has evolved over the years to be more
accommodating to patients. The battery-oper-
ated device is continuously worn external to the
body, requiring a commitment by patients, their
families, and providers to ensure its consistent,
appropriate use. The use of the pump has risen
sharply in the past few years, particularly
among adolescents, suggesting its convenience
and efficacy for maintaining good blood glucose
levels without the need for injection twice to
four times daily.37 Compared to traditional in-
tensive insulin therapy, the insulin pump has
achieved a 10% greater reduction in blood glu-
cose levels when used by patients age 12 to 20.
According to results from the DCCT, this could
translate to a reduction in retinopathy (diabetic
eye disease) of up to 42%.38
Future delivery systems. Although pens and
pumps have allowed people with diabetes
some degree of choice and convenience, other
insulin delivery devices currently in develop-
ment could expand future options. The pri-
mary objective of many of these devices is to
reduce or obviate the necessity of needles en-
tirely. Inhalers containing insulin powders and
liquids are now being tested, as are transdermal
patch systems and oral sprays.15 Although these
methods require further testing to elucidate their
safety and efficacy, there is a real possibility of a
noninjectable insulin in the relatively near future.
Such innovations will give people with diabetes
greater latitude in their choice of treatment op-
tions, allowing them to match their treatment to
their own wants and needs. Inhalers and patches
may work well for people who travel often, who
cannot easily interrupt work or other activities
to inject, or who are simply uncomfortable with
needles. But each method may not work for
everyone (e.g., patients with lung impairment
may not benefit from inhaled insulin), nor will
any one method completely remove the need for
injections for everyone (e.g., inhalers will proba-
bly be adjunctive therapy to long-acting and in-
termediate-acting injections). The availability of
alternative delivery devices and dosage forms
and routes of administration will allow for
greater individualization of care, perhaps en-
couraging greater adherence and tighter blood
glucose control, and thus improving clinical and
economic outcomes.
Despite many innovations, managing diabetes
consistently over time is still a challenge. No one
particular management strategy will work for
everyone with diabetes for several reasons: the
dual nature of the disease (type 1 vs. type 2), its
multifactorial etiology including genetic, physi-
ologic and environmental factors, and the diver-
sity of individual sufferers. Therefore, identify-
ing an effective strategy for managing diabetes
is best accomplished on a case-by-case, patient-
by-patient basis.9 Table 3 compares diabetes
management strategies in terms of indications,
benefits, and major side effects.
INDIVIDUALIZING CARE FOR
PATIENTS WITH DIABETES
Why is individualized pharmaceutical care needed?
Controlling diabetes demands individual-
ized patient care for several mutually depen-
dent reasons. First, the origin of disease in 
diabetes is complicated, dynamic, and multi-
factorial. Second, the diabetic population is be-
coming more diverse in age, ethnicity, overall
health, and other characteristics. Third, dia-
betes often occurs concurrently with other
medical conditions, especially in certain groups
such as the elderly. These factors suggest that
pharmaceutical care should be tailored to meet
patient-specific characteristics and needs. For-
tunately, there are many diabetes medications
available in different dosage forms and quan-
tities with varying duration of action, mecha-
nism of action, and side-effect profiles. Despite
the array of choices, there are still sufferers who
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have not responded to treatment; new medica-
tions are currently in development for this
therapy resistant population, and continued re-
search efforts are warranted.
A disease with a complex etiology
Identifying and managing diabetes is com-
plex because of its dual nature (type 1 vs. type
2) and its multifactorial origins. Genetic and en-
vironmental factors are believed to play a sig-
nificant role in both types of diabetes. Type 1
diabetes usually begins in childhood and is
caused by an abnormal autoimmune process
that destroys cells in the pancreas, which
makes insulin.23 This accounts for the total ab-
sence of insulin, the hallmark of type 1 dia-
betes, which requires daily insulin therapy to
sustain the patient. While environmental fac-
tors, such as diet and exercise, can affect the
management of type 1 diabetes, they do not
cause the disease.
In type 2 diabetes, genetic and environmen-
tal causes are difficult to untangle. Studies have
indicated that the condition aggregates in fam-
ilies, especially those with a preponderance of
obese and/or sedentary family members.6 It re-
mains unverified whether this link is geneti-
cally or environmentally determined, but in all
likelihood familial type 2 diabetes probably
stems from both factors. In addition, children
of women who develop diabetes during preg-
nancy have a greater chance of developing it
themselves compared to those whose mothers
develop diabetes after pregnancy. This sug-
gests prenatal involvement.6
One theory, the “thrifty genotype hypothe-
sis,” suggests that nutritional deprivation dur-
ing fetal development increases the likelihood of
type 2 diabetes. Some infants may have a spe-
cific genetic makeup that allows them to survive
despite low levels of prenatal nutrition, but this
same genotype increases their risk of develop-
ing diabetes. Metabolism and insulin resistance
may also be genetically linked to diabetes, but
according to diabetes researcher Peter Bennett,
“genetic determinants have been difficult to elu-
cidate because there are multiple biochemical
and metabolic abnormalities, probably poly-
genic, and the situation is complicated by envi-
ronmental factors and late age of onset.”6
In addition, physiologic changes that occur
with age factor into the diabetes equation, both
in terms of onset and treatment. Changes such
as alterations in metabolism and body compo-
sition affect glucose tolerance in almost every-
one. As people age, some impairment in glucose
blood levels occurs, with average increases of 5
to 10 mg/dL per decade after age 50.39 But for
more than half the population over age 65, these
age-related physiologic changes, coupled with
other factors such as nutrition and activity level,
lead to clinically diagnosable type 2 diabetes.39
Diabetes in special populations
All the factors implicit in the origins of dia-
betes—family genetics, environment and be-
havior, and the physiology of aging and co-
morbidity—contribute to subpopulations at
special risk for developing the disease. Dia-
betes may also manifest or progress differently
in these high-risk groups. Likewise, the man-
agement of diabetes in subpopulations can be
varied to meet the diversity of group and in-
dividual healthcare needs. This section takes a
closer look at several groups for whom diabetes
prevention and individualized treatment is es-
sential to ensuring positive health outcomes.
Diabetes in women. Diabetes affects more than
8% of all women in the United States, a per-
centage that is similar to that in the male popu-
lation. But although men and women are at
equal risk for developing diabetes, the reper-
cussions of the disease can be particularly dan-
gerous for women. For example, women with
diabetes have an increased risk of complications
during pregnancy. Also, women have a much
greater chance (up to 50% higher) than their
male counterparts of developing diabetic ke-
toacidosis, which poses a serious health threat.40
Compared to women without diabetes,
women with diabetes are nearly eight times
more likely to suffer from peripheral vascular
disease (PVD) in which blood and oxygen flow
to the lower extremities is reduced. PVD causes
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intermittent claudication (leg pain during ex-
ercise), and this condition predisposes the suf-
ferer to a 3 to 4 times greater risk of several car-
diovascular diseases.13,40
Women with diabetes who are also pregnant
face the possibility of additional complications.
Because the body demands more insulin during
pregnancy, extremely strict blood glucose con-
trol is essential for women who are pregnant or
trying to conceive. The early infant mortality rate
for babies born to mothers with diabetes is as
much as two to three times higher compared to
children of women who do not have diabetes.
Moreover, this risk increases when preconcep-
tion care of the mother is inadequate or absent.
Pregnant women with diabetes are at increased
risk of having high birthweight newborns, thus
increasing the need for cesarean section to three
to four times that of the general population. Dan-
gers also include greater risks of toxemia and hy-
dramnios (excessive accumulation of the amni-
otic fluid). Both are serious health concerns for
the mother and child.40
Even women who do not have diabetes when
they conceive are still at risk for an alternate
form of the condition known as gestational di-
abetes. Gestational diabetes develops in 2% to
5% of all expectant women without diabetes
but resolves after pregnancy. However, gesta-
tional diabetes increases the chances of com-
plications during pregnancy and increases the
chances of both child and mother developing
type 2 diabetes postdelivery.41
Diabetes in children and adolescents. Diabetes is
the most common severe chronic disease of
childhood. The majority of children and adoles-
cents with diabetes are diagnosed with type 1
disease. Type 1 diabetes in children usually oc-
curs during puberty, and the disease runs in fam-
ilies, suggesting a genetic component. Unlike
type 2 diabetes, the incidence of type 1 diabetes
is greater in whites than in other racial groups.
The number of youths with type 2 diabetes
is growing. Children with type 2 diabetes tend
to be overweight and slightly older at diagno-
sis, compared to youths with type 1 diabetes.
They may have a family history of type 2 dia-
betes and are also likely to be African Ameri-
can, Native American, or Latino.
Treatment of children with diabetes requires
special consideration. Studies suggest that
achieving and maintaining an optimal blood
glucose level is especially important in this age
group. The Pittsburgh Epidemiology of Dia-
betes Complications Study revealed a relation-
ship between glycemic control and disease
complications in childhood onset diabetes.41 In
cases where there was very poor gylcemic con-
trol, retinal complications have occurred before
puberty. While the evidence is conflicting, the
number of years a child lives with diabetes be-
fore puberty may correlate with an increased
risk for future vascular complications.42
The nature of childhood itself uniquely af-
fects diabetes and its management. Special con-
siderations must be taken into account for this
population. Intense activity during play or
sports, high sugar and fat content of snack
foods marketed toward children, and the gen-
eral level of personal responsibility for self-care
all significantly impact blood glucose levels
and diabetes management in children. One key
to successful treatment is consistent blood glu-
cose monitoring followed by therapeutic and
behavioral adjustments to reach optimal lev-
els.42 Depending on age, children may or may
not be old enough or responsible enough to un-
derstand and adhere to a program of monitor-
ing and management. Adherence among chil-
dren can be increased by intensive diabetes
education for the patient and his or her family.
For children taking insulin who require more
flexibility in daily activity and dietary habits,
four injections per day, compared to two, may
result in better glycemic control.42
For all of these reasons, childhood diabetes
requires early detection and individualized
treatment to optimize outcomes at onset and
throughout later life. More research is required
to determine the special characteristics unique
to children with diabetes to maximize the suc-
cess of current therapies or suggest innovations
that could improve diabetes care for children.
Whatever therapy is selected, tight glycemic
control is essential for good outcomes.
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Diabetes in the elderly. The elderly are dis-
cussed in the diabetes medical literature more
than any other patient population identified in
this paper. Perhaps the abundance of literature
reflects the significant impact diabetes has on
seniors: half of all people with diabetes are
older than 55 years of age.40 Because aging is
an independent risk factor for type 2 diabetes,
everyone has a vested interest in understand-
ing diabetes prevention, risk factors, and early
detection. For those people who do acquire di-
abetes during their adult or later adult lives,
understanding diabetes management options
is critical as well.
What are the special considerations for older
patients with diabetes? Primarily, the compli-
cations of diabetes are more prevalent and
more dangerous for older individuals. Because
aging reduces the body’s physiologic reserves,
alters its metabolism, and diminishes organ
function, diabetes complications are more com-
mon in this age group. For example, the preva-
lence of diabetic heart disease increases with
age. Likewise, kidney infections are twice as
common in the 65-plus diabetic population as
in the population without diabetes.40 In addi-
tion to complications caused by diabetes, the
increased prevalence of comorbidities in older
patients is a special concern for people with di-
abetes. Comorbidity, or the coexistence of two
or more diseases, occurs more often with age,
and its presence increases morbidity, mortality,
and medical resource use.43 The specific con-
cerns associated with diabetes with comorbid-
ity are discussed later in this paper.
One specific concern about diabetes in the el-
derly is their increased risk of hypoglycemia.
Because the risk of hypoglycemic episodes is
greater in the aged, monitoring blood glucose
levels carefully is essential, especially when hy-
poglycemic medications are used. First-line
treatment should include diet and exercise
modifications, if possible. Then, if pharma-
cotherapy is required to control blood glucose
levels, selection should be based on the pa-
tient’s individual needs.
However, some diabetes medications should
generally be avoided in the elderly. For example,
chlorpropamide, an oral sulfonylurea, has a long
half-life and high incidence of hypoglycemia and
is not preferable for most older patients.9 A bet-
ter option in this class of drugs are shorter-act-
ing, less hypoglycemic agents such as glipizide.
When initiating drug therapy, elderly who may
have altered metabolism should begin with half
the recommended dosage given to younger pa-
tients and titrate to a therapeutic level. Also, pa-
tients with renal or hepatic insufficiency should
not be treated with sulfonylureas.
Diabetes in certain racial and ethic groups: His-
panic Americans, Native Americans, African Amer-
icans face greater risks. Similar to the elderly, cer-
tain ethnic and racial groups face greater risks
of type 2 diabetes and its complications. The
comparative prevalence of type 2 diabetes in
these groups is astounding: 24% of all Mexican
Americans, 26% of all Puerto Ricans, 11% of
African Americans, 12% of Native Americans,
and 16% of Cuban Americans have diabetes
compared to 6% in the general population.
Asian Americans and Pacific Islanders appear
to be at greater risk also, although prevalence
data are limited.2 In one specific tribe of Native
Americans residing in Arizona, the prevalence
of type 2 diabetes is higher than in any other
group worldwide, with 50% of adults ages 30
to 64 having the disease. Among Native Amer-
icans overall, complications from diabetes are
the most frequent cause of death from disease.
Several factors account for higher rates of di-
abetes morbidity and mortality in ethnic
groups. Environmental factors may include ac-
cess to quality, affordable healthcare, varying
levels of functional health literacy, effective pa-
tient education, diet, exercise, and other health
behaviors including alcohol and tobacco use.
Although these socioeconomic and behavioral
factors play a considerable role, recent research
concludes that ethnicity alone is strongly asso-
ciated with diabetes and its control in some mi-
norities.44 This finding implicates genetic vari-
ables as risk factors for type 2 diabetes; if so,
recent and ongoing research in genomics and
biotechnology could offer improved care op-
tions for subpopulations with a predisposition
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to the disease. At any rate, the conclusions sug-
gest that continued efforts to support biotech-
nological innovation are warranted to promote
equitable diabetes care for minority groups.
Diabetes and comorbidity
Comorbid conditions are common in pa-
tients with diabetes. In many cases, diabetic
complications account for these conditions; in
others, the coexisting condition(s) precedes or
occurs independent of diabetes. In either situ-
ation, comorbidity requires specialized care
regimens to optimize clinical outcomes. Co-
morbidity often generates disease synergies
more debilitating than the additive effects of
each individual disease. Common comorbidi-
ties in patients with diabetes include obesity,
cardiovascular diseases, depression, and nerve,
eye, and kidney diseases. While a discussion of
all diseases that commonly coexist with dia-
betes is too broad for the scope of this paper,
the following sections focus on two major co-
morbid illnesses associated with diabetes: car-
diovascular conditions and depression.
Diabetes and cardiovascular conditions. Re-
searchers have extensively studied the connec-
tion between diabetes and cardiovascular dis-
ease (CVD). In the United States, cardiovascular
disease is the leading cause of death in both men
and women with diabetes. The mortality rate
associated with CVD is significantly higher in
women than in men and increases with ad-
vancing age in both men and women.13
When treating patients with comorbid dia-
betes and CVD, minimizing the deleterious ef-
fects of both conditions is essential. If the treat-
ment of one disease is emphasized over the
other, the undertreated disease can exacerbate
the seemingly well-managed one. However, in-
tensive risk factor modification improves the
prognosis of patients with comorbid diabetes
and CVD.45 Many risk factors, such as poorly
controlled blood glucose levels, hypertension,
and dyslipidemia, can be minimized with drug
therapy.
The Multiple Risk Factor Intervention Trial
(MRFIT), a 12-year analysis of coronary heart
disease (CHD), revealed higher mortality rates
for patients with diabetes. Hypertension, hy-
percholesterolemia, and cigarette use further in-
creased these rates in individuals with dia-
betes.45 Controlling these risk factors with
pharmacotherapy can reduce the risk of car-
diovascular events. Strict control of blood pres-
sure and blood glucose levels appears to be a
primary therapeutic goal.13 Blood pressure can
be reduced by using various classes of anti-
hypertensive agents such as diuretics, angio-
tensin-converting enzyme (ACE) inhibitors, b-
blockers, and calcium channel blockers. Within
each drug class, there are numerous agents
from which to choose. The specific choice of an
antihypertensive agent is important in that, first
and foremost, it must reduce blood pressure,
and second, it should be selected to meet spe-
cific patient needs, taking into consideration
age, comorbidities, and other health factors.
Antihypertensives agents that increase blood
glucose levels (e.g., diuretics) should be
avoided in patients with diabetes. Recently, as-
pirin therapy has also been recommended by
the American Diabetes Association as a consid-
eration for adults with diabetes who have CVD
or CVD risk factors. While nearly every diabetic
adult in the United States has at least one risk
factor for CVD, only 20% take aspirin regu-
larly,46 suggesting that undertreatment may
play a large role in inadequately controlled risk
factors for comorbid diabetes and CVD.
Diabetes and depression. Although not usually
indicated as a complication of diabetes in the
same way as heart disease and obesity, depres-
sion is a common comorbid condition facing
many patients. A recent study by Anderson and
colleagues47 concludes that having diabetes
doubles the odds of comorbid depression. This
National Institutes of Health (NIH)-sponsored
meta-analysis of 42 diabetes/depression stud-
ies showed that major depression was present
in 14.7% and elevated depression symptoms in
26% of diabetic patients.47
Now that the medical community generally
acknowledges that mental status can impact the
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course of comorbid physical illnesses,11 these
rates of depression are a serious consideration in
terms of treating people with diabetes. However,
studies have suggested that even in the general
population, depression is undertreated.48
Inadequate treatment of depression in pa-
tients with diabetes further compromises health
status for several reasons. First, a depressed pa-
tient may not be motivated to follow the rigid
self-care routines required to maintain good
blood glucose control. Second, depression often
results in appetite and weight fluctuations that
can impact diabetes progression or encourage
undesirable and dangerous hypoglycemic or
hyperglycemic events. In addition, diabetes can
negatively impact major depression by increas-
ing the frequency of recurrent depressive
episodes in the five years following diagnosis.11
Diabetes increases the risk of subclinical de-
pressive symptoms as well.47
Recent reports reveal that treating comorbid
depression in patients with diabetes can im-
prove glycemic control without interfering with
diabetes medications. Both tricyclic antidepres-
sants and selective serotonin reuptake inhibitors
(SSRI) have shown efficacy in treating depres-
sion.49 However, SSRIs offer fewer side effects
and a lower risk of a direct hyperglycemic ef-
fect.11,50 A more recent study of patients with di-
abetes with depression showed that after only 8
weeks of treatment with the SSRI fluoxetine, de-
pressive symptoms decreased, and glycemic
control showed improvement.51
PROMOTING QUALITY, COST-
EFFECTIVE DIABETES MANAGEMENT
THROUGH INDIVIDUALIZED CARE
With the efficacy of intensive, individualized
diabetes treatment established, the medical re-
search community is now focused on how to
achieve this outcome in a cost-effective man-
ner. The primary cost of treating diabetes
comes from short-term hyperglycemia and
long-term complications.52 One analysis of in-
tensive treatment of type 2 diabetes found that
achieving normal blood sugar levels would re-
duce the incidence of blindness by 72% and
end-stage renal disease by 87%, lower extrem-
ity amputation by 67%, and raise life ex-
pectancy by 1.4 years.53 Importantly, these facts
and figures imply that good clinical and eco-
nomic outcomes are aligned. By reducing the
incidence of diabetes complications, costs
would decrease as well.
Improved clinical practice in diabetes man-
agement is one step toward quality, cost-effec-
tive outcomes. In July 1995, the American Dia-
betes Association convened a panel of experts
to develop a consensus statement on the phar-
macologic treatment of hyperglycemia in type
2 diabetes. The panel, relying on evidence from
the DCCT, recommended that if progress to-
ward glycemic goals was not apparent within
a 3-month period after initiation of diet and ex-
ercise, then use of a pharmacologic agent is ap-
propriate.26 Before the availability of antidia-
betic drugs, approximately 35% of type 2
patients were treated with insulin alone. While
clinically effective for glycemic control, insulin
therapy requires diligent compliance on the
part of the patient. For some individuals—es-
pecially children, the elderly, and patients with
low functional health literacy—complying
with a rigid drug regimen is a considerable
task. Thus, achieving this compliance presents
the clinician with the challenge of educating the
patient about self-administration and dose ad-
justment.54 Moreover, compliance is linked to
factors such as side effects, ease of administra-
tion, affordability of medication, and the pa-
tient’s perception of effectiveness. Therefore,
selecting the specific combination of medica-
tions that will meet an individual patient’s
needs is essential to encouraging compliance
and improving outcomes.
Fortunately, the array of independently act-
ing antidiabetic medications available makes
possible a number of combination therapies,
and recent research focusing on the efficacy of
particular combinations has revealed opportu-
nities where judicious selection among antidi-
abetic agents of similar efficacy may have ben-
eficial effects on complications of diabetes or
comorbid conditions.
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The availability of antidiabetics agents with
complementary mechanisms of actions allows
clinicians to select treatments that have addi-
tive benefits and avoid detrimental side effects.
A meta-analysis of nine randomized con-
trolled trials published since 1957 was con-
ducted in 1999 to compare the efficacy of
biguanides and sulfonylureas. Although the ef-
ficacy is similar for biguanides and sulfonyl-
ureas, sulfonylurea treatment was associated
with an increase in body weight, and biguanides
with a decrease, suggesting that a biguanide
may be preferred for obese patients.55
DIABETES PUBLIC POLICY
IMPLICATIONS
Healthy People 2010, the nation’s comprehen-
sive plan for improving public health, includes
goals for reducing the burden of diabetes and
improving the quality of life for all persons who
have or are at risk for the disease. Specifically, it
states a goal of reducing by 10% the number of
deaths from CVD in persons with diabetes. Over
the past ten years, diabetes has been a leading
cause of death in the United States, primarily due
to diabetes-related CVD. Achieving reductions
in addressable risk factors, such as uncontrolled
hypertension, smoking, and high cholesterol,
could significantly reduce the incidence of CVD
in persons with diabetes.
Related goals in Healthy People 2010 are di-
rected toward reducing the incidence of other
costly, life-shortening complications among
patients with diabetes, including end-stage re-
nal disease, blindness, lower extremity ampu-
tation, and complications of pregnancy. Be-
cause weight reduction ameliorates metabolic
abnormalities characteristic of diabetes and
may help prevent complications of the disease,
addressing overweight and obesity is of major
importance in reaching this goal.
To reach the Healthy People 2010 goals, there
must be improvements in the practice of
healthcare for people with diabetes. Measure-
ment and monitoring of glycosylated hemo-
globin (HbA1c) levels is the gold standard for
glycemic control as specified in guidelines, yet
it is still underused, especially in primary
care.56 There is considerable interest in the ef-
fect of managed care on diabetes treatment
patterns. Interest has grown with the spread
of managed care coverage to higher-risk
Medicare beneficiaries in the late 1990s. Re-
ferral to out-of-network physicians and spe-
cialists is a more complex process in managed
care; therefore, diabetics are relying increas-
ingly on care and education from their pri-
mary care physicians.
The long-term impact of managed care on di-
abetes treatment patterns is still not known;
however, some believe increased use of oral an-
tidiabetic agents may be attributed in part to
managed care practices. Moreover, with the in-
troduction of diabetes treatment-related per-
formance measures into the National Commit-
tee for Quality Assurance, Health Plan
Employer Data and Information Set (HEDIS®),
many managed care plans have developed
comprehensive diabetes treatment programs to
promote early detection of diabetes and related
conditions through educational programs and
screenings. While front-end financial invest-
ments such as increased drug spending and di-
abetes disease management are costly, the po-
tential return-on-investment could be doubly
advantageous. By improving clinical outcomes
through better diabetes prevention and man-
agement, overall expenditures, especially those
associated with long-term complications, could
be significantly reduced.
DIABETES: a tool for a complex condition
Creating cost-effective diabetes management
plans to meet the individual needs of a diverse
patient population is dependent on many fac-
tors. When one or more of these factors are over-
looked, therapy plans may be less than optimal,
clinical outcomes less positive than expected,
and financial returns inconsequential. A com-
plex condition such as diabetes requires a com-
prehensive strategy to address clinical and eco-
nomic outcomes adequately. To help ensure that
all factors are considered, we have designed a
mnemonic tool to remind patients, providers,
and policy-makers of the many facets of indi-
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vidualized diabetes care. Our DIABETES device
addresses what we believe to be the essential
components of individualizing pharmaceutical
therapy in the treatment of diabetes.
Delivery: Matching a dose delivery method
with a patient and his or her special needs is a
key step toward ensuring compliance and en-
couraging good glycemic control. Patients who
are comfortable with their insulin delivery sys-
tem will be more willing and better able to ad-
here to their diabetes plans.
Integration of Care: When all care providers
and sites are well integrated, the opportunity
to maximize the quality of diabetes care is at
its peak. Integrated care includes communica-
tion among physicians, specialists, pharma-
cists, nurses, and other people involved in the
patient’s care process. It also means that sys-
tems and programs have been implemented to
easily facilitate such communication. For ex-
ample, information-sharing systems supported
by Web-based and electronic tools can connect
all of a patient’s care providers, and in some
cases even the patient, to form a network of in-
tegrated care for each individual. Also, inte-
grated disease management (DM) programs
that address multiple therapeutic areas, such as
the combined diabetes and heart disease DM
programs that have recently evolved, are cre-
ating care processes that address the complex-
ity of diabetes and comorbid disease.
Adherence:Adherence may be more important
in diabetes than in any other disease state. Ad-
herence promotes strict glycemic control, and
glycemic control is the best method for con-
trolling diabetes and preventing its complica-
tions. That is why promoting adherence is vital
to diabetes care. Adherence can be encouraged
through offering intensive diabetes education,
creating convenient dosing regimens to fit in-
dividual lifestyles, addressing the emotional
and psychological needs of patients with dia-
betes, minimizing medication side effects, pro-
viding following-up care through PCP, nurse
practitioners or structured DM programs, and
designing accessible and affordable diabetes
management plans for individual patients.
Behavior Change: To promote individualized
care for people with diabetes, behavior change
will need to occur at the patient, provider, and
policy level. We know this because although ef-
fective diabetes diagnostics, therapies and treat-
ment guidelines exist, there are still nearly 5 mil-
lion cases of undiagnosed diabetes in America.
Of the patients who are diagnosed, many still
suffer uncontrolled blood glucose levels that can
lead to costly clinical complications. The tools to
prevent and manage diabetes are out there, and
new and improved tools are developed every
day. But the systems, processes, and individual
behaviors of all diabetes stakeholders must max-
imize the use of these tools if the fight against
diabetes is to succeed. Behavior change can be
affected through education, incentives, policies,
and regulations. All of these methods must be
explored to enhance diabetes outcomes.
Education: Education that occurs at every con-
tact point between the patient and care
providers is needed. Providers who take ad-
vantage of every “teachable moment” will be
most successful in helping their patients de-
velop the skills and attitudes that they need to
manage their diabetes. Opportunities for edu-
cating patients may be less formal, such as im-
promptu discussions during office or phar-
macy visits, or more structured, such as
planned patient education meetings offered as
part of a larger diabetes DM program. Educa-
tion can be provided in many modalities—pa-
tient literature, videos, one-on-one, or group
instruction. Studies have shown clearly that a
patient’s functional health literacy is directly
connected to the kind of care he or she seeks
and receives and to health outcomes. There-
fore, maximum effort is needed to provide di-
abetes education that reaches all patients.
Treatment Options: Each year, the American
Diabetes Association, with the support of ex-
pert clinicians and researchers, reviews and re-
vises treatment guidelines and recommenda-
tions for caring for people with diabetes. These
guidelines, along with the myriad of pharma-
cologic and nonpharmacologic treatment op-
tion for diabetes, provide the foundation for
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quality diabetes care. Yet the existence of
guidelines and treatment options is not
enough. The wide range of diabetes medica-
tions must be made available for all patients if
individualized care is to be achieved.
Economics: Healthcare coverage, be it private
or publicly funded, that limits access to the full
span of diabetes medications could compro-
mise health outcomes for patients. Moreover,
we know that compromised health outcomes
in diabetes lead to extraordinarily expensive
complications. The front-end costs associated
with quality preventive diabetes care and man-
agement are an investment that has the poten-
tial to alleviate at least a portion of the finan-
cial burden associated with the high costs of
uncontrolled diabetes. Controlling diabetes
may be expensive, but is it as expensive as al-
lowing the disease to run rampant through our
national and personal healthcare resources?
Special Circumstances: For pharmaceutical
care to be truly individualized, any special cir-
cumstances regarding the patient need to be
considered when developing a treatment plan.
Although this is to some degree true for any
disease or medical condition, it is especially rel-
evant in the case of diabetes because of its per-
vasiveness. Diabetes infiltrates all aspects of an
individual’s life, from what to choose for break-
fast to how to schedule daily activities around
administering medications and monitoring
blood glucose levels. Therefore, any situations
that are unique to an individual patient have
the potential to impact the diabetes care plan.
Examples of such factors include socioeco-
nomic issues like living environment, trans-
portation, and financial resources as well as
clinical issues such as comorbidities and gen-
eral health status. At least one individual on
the patient’s diabetes care team needs to be pre-
pared to discuss any issue that might impact
the diabetes treatment plan.
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